Loading stock data…
CVM
$2.28-0.79 (-25.73%)
Market ClosedLast close May 1
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CEL-SCI Corporation in the Healthcare sector is trading at $2.28. The stock is currently near its 52-week low of $1.98, remaining 65.0% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why CVM maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.28
Potential Upside
5%
Whystock Fair Value$2.39
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$25.00+996.5%
Range$25.00 – $25.00
Fundamentals
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has complete...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-213.74%
Volume
Today's trading volume
769,950
Recent News
Cel-Sci: Fiscal Q1 Earnings Snapshot
VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Tuesday reported a loss of $5.5 million in its fiscal first quarter.
Cel-Sci: Fiscal Q3 Earnings Snapshot
VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Thursday reported a loss of $5.7 million in its fiscal third quarter.
Cel-Sci: Fiscal Q2 Earnings Snapshot
VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Wednesday reported a loss of $6.6 million in its fiscal second quarter.